Trial Profile
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Reparixin (Primary)
- Indications Delayed graft function
- Focus Therapeutic Use
- Sponsors Dompe Farmaceutici
- 25 May 2021 Primary endpoint (Proportion of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 36514 Days After Transplant.) has not been met, according to results published in the American Journal of Transplantation.
- 25 May 2021 Results assessing efficacy and safety of Reparixin in patients who were insulin independent Day 365 after TPIAT, published in the American Journal of Transplantation.7
- 12 Jun 2018 Status changed from active, no longer recruiting to completed.